Search
Search Results
-
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial....
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves...
-
Does Inflammation Play a Major Role in the Pathogenesis of Alzheimer's Disease?
Alzheimer's disease (AD) is a neurodegenerative disease leading to dementia for which no effective medicine exists. Currently, the goal of therapy is...
-
An insight into prodrug strategy for the treatment of Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. With 35 million people over 60 suffering from dementia, new treatments for AD...
-
Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease
Most scholars believe that amyloid-beta (Aβ) has the potential to induce apoptosis, stimulate an inflammatory cascade, promote oxidative stress and...
-
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
BackgroundApolipoprotein E (ApoE) ε4 genotype is the most prevalent risk factor for late-onset Alzheimer’s Disease (AD). Although ApoE4 differs from...
-
Gene therapy: an alternative to treat Alzheimer’s disease
Alzheimer’s disease (AD), a neuro-degenerative disease that primarily affects the elderly, is a worldwide phenomenon. Loss of memory, cognitive...
-
Nanotechnology and Nature-Sourced Ingredients for Tackling Neurodegenerative Diseases
Neurodegenerative diseases (NDDs) pose a significant and pressing societal challenge in the twenty-first century, demanding immediate attention....
-
Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy
Alzheimer’s disease (AD) is the most common type of human dementia and is responsible for over 60% of diagnosed dementia cases worldwide. Abnormal...
-
Deciphering New Drug Targets in Alzheimer’s Disease
Alzheimer’s disease (AD) currently has no known treatments that can reverse the disease or cure it. Numerous pharmacological targets have already...
-
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
The use of biomarker-led clinical trial designs has been transformative for investigating amyloid-targeting therapies for Alzheimer’s disease (AD)....
-
Recent Progress in the Treatment Strategies for Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurological ailment that affects older people and causes a steady decline in their cognitive function. The cognitive...
-
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Alzheimer’s disease (AD) is a priority health problem in developed countries with a high cost to society. Approximately 20% of direct costs are...
-
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Scientific advances over the last four decades have steadily infused the Alzheimer’s disease (AD) field with great optimism that therapies targeting...
-
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
Ageing is a crucial risk factor for Alzheimer’s disease (AD) and is characterised by systemic changes in both intracellular and extracellular...
-
Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer’s Disease: Recent Trends and Future Development
Alzheimer’s disease (AD) is the primary cause of dementia and is characterized by the death of brain cells due to the accumulation of insoluble...
-
Involvement of α7nAChR in the Protective Effects of Genistein Against β-Amyloid-Induced Oxidative Stress in Neurons via a PI3K/Akt/Nrf2 Pathway-Related Mechanism
Abnormal excessive production and deposition of β-amyloid (Aβ) peptides in selectively susceptible brain regions are thought to be a key pathogenic...
-
Sulfur-containing therapeutics in the treatment of Alzheimer’s disease
Sulfur is widely existent in natural products and synthetic organic compounds as organosulfur, which are often associated with a multitude of...
-
Effect of Riluzole, a Glutamate Release Inhibitor, on Synaptic Plasticity in the Intrahippocampal Aβ Rat Model of Alzheimer’s Disease
Alzheimer’s disease (AD) is associated with cognitive deficits of varying degrees and with impairment of the synaptic transmission-related tasks....
-
Butyrylcholinesterase in Substance Abuse: An Overview
Substance abuse places a great burden on associated families, communities, and the health care sector. Drug addiction leads to physical traumas,...
